Table III.
Decision to Continue Current Treatment or Titrate for Home and Office BP
| OBP, % | HBP, % | Agreement, % | |
|---|---|---|---|
| Atenolol | |||
| Continue | 143 (68) | 127 (60) | 109 (52) |
| Increase treatment | 67 (32) | 83 (40) | 49 (23) |
| Total | 158 (75) | ||
| Hydrochlorothiazide | |||
| Continue | 130 (63) | 103 (50) | 84 (40) |
| Increase treatment | 78 (38) | 105 (50) | 59 (28) |
| Total | 143 (69) | ||
| Combination | |||
| Continue | 322 (83) | 331 (86) | 320 (77) |
| Increase treatment | 65 (17) | 56 (14) | 25 (6) |
| Total | 345 (83) | ||
Abbreviations: BP, blood pressure; HCTZ, hydrochlorothiazide. Decision to continue current treatment using office BP (OBP) <140/90 mm Hg or home BP (HBP) <135/85 mm Hg. P<.02 for continue/increase vs treatment group (atenolol/HCTZ) in HBP. P=.23 for continue/increase vs treatment group (atenolol/HCTZ) in OBP.